Acostill ( RaDiCo Cohort) (RaDiCo Acostill)

NCT05927454 | Recruiting

• 1 other identifier: C15-48
• Study Type: observational
• Target: 500
• Locations: 1 country
• Sites: 1

Brief Summary

Adult Onset Still Disease (AOSD) and Systemic onset Juvenile Idiopathic Arthritis (SoJIA) are two rare multifactorial diseases associated with systemic inflammation. These two forms AOSD and SoJIA are considered to be two facets of the same syndrome, combining four cardinal symptoms \[hectic fever\> 39 °, arthralgia or arthritis, skin rash, a leukocyte formula with more than 80% of neutrophils\]; lymphadenopathy and splenomegaly may also be found. There is an important biological inflammatory syndrome with elevation of the reactive C protein, of serum ferritin with a dramatic drop in the glycosylated fraction. The incidence of the disease is low, around 0.1/100,000 for adults and 0.6/100,000 for children. Its prevalence is approximately 1 to 3/100,000 and 3/100,000 for children, so there are approximately 500 to 1,500 adults and 450 children affected in France. It is subdivided into pediatric and adult forms according to the age of onset before or after 16 years. The prognosis of the disease is functional and vital. Macrophage activation syndrome (SAM) is frequently associated with either the onset of the disease or the initiation of treatment or concomitantly with viral reactivation. The course over time has mainly been studied in children and is variable: regression, course by flare-ups with term regression and chronic joint development. In adults we can also observe these 3 evolutionary modes. However, differences seem to exist between AOSD and SoJIA. The various clinical questions posed by this disease are as follows:

• Why does it differentially affect two age groups of the population?
• Why is the clinical expression heterogeneous with pure systemic or articular forms, the frequency of SAM, and rare organ damage?
• Why is the evolution over time different with resolving monocyclic forms or polycyclic forms and sometimes chronic evolutions? These differences could be explained by distinct underlying pathogenic mechanisms. But at present, the pathophysiology of this entity remains unknown, although several hypotheses can be formulated involving several pathophysiological pathways. The pathogenesis of Still's disease has not yet been elucidated but there is a significant inflammatory reaction without the production of autoantibodies, which makes this disease a form of autoinflammatory syndrome with abnormalities of the innate immunity (activation of macrophages, strong elevations of pro-inflammatory cytokines: interleukins 1 and 18, possible abnormalities of inflammasomes and NK cells). The treatment is based on anti-inflammatory drugs, corticosteroids with the usefulness of methotrexate and anti-TNF in the event of significant joint damage. Interleukin 1 and 6 inhibitors have been shown to be effective in this disease. In adults and children, there are forms that are refractory to treatment, with a risk of AA amyloidosis for these patients. The expected outcomes of this work are to improve knowledge of Still disease and patient management on the following aspects:
• Comparison of pediatric and adult forms (which has never been done on a large number of patients),
• Better understanding of the pathogenic mechanisms of the disease,
• The identification of early diagnostic/prognostic markers,
• The possibility of promoting the evaluation of new therapies to come thanks to the constitution of an active file of patients with a standardized follow-up. The ACOSTILL study group is thus a unique collaboration of adult clinicians (rheumatologists and internists) and pediatricians, who have decided to unite their efforts to increase knowledge about the pathogenesis of Still disease in order to better understand the disease and improve care pathways. Many of them participated in the development of the national diagnostic and care protocol published in 2018.

Conditions

Still's Disease, Adult-Onset; Still Disease; Still Disease, Juvenile Onset

Keywords

Still Disease; Rare disease; Diagnostic markers; Prognostic markers; New therapies

Outcome Measures

Primary Outcomes (4)

• General signs of the disease

  Through study completion, at 1 year, 2 year, 3 year, 4 year, 5 year

• Clinical signs of the disease

  Through study completion, at 1 year, 2 year, 3 year, 4 year, 5 year

• Biological results

  Through study completion, at 1 year, 2 year, 3 year, 4 year, 5 year

• - The impact of the disease on the patient's daily life

  Through study completion, at 1 year, 2 year, 3 year, 4 year, 5 year

Secondary Outcomes (4)

• Quality of life scores

  Through study completion, at 1 year, 2 year, 3 year, 4 year, 5 year

• AIDAI scores

  Through study completion, at 1 year, 2 year, 3 year, 4 year, 5 year

• Prospective biomarkers

  Through study completion, at 1 year, 2 year, 3 year, 4 year, 5 year

• Presence of autoinflammatory disease in relatives

  Through study completion, at 1 year, 2 year, 3 year, 4 year, 5 year

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

In order to reflect the reality of daily practice, all pediatric and adult patients already diagnosed and monitored (prevalent patients) or newly diagnosed (incident patients) in one of the French Rare Disease Reference Center or Rare Disease Competence Center will be invited. to participate in the study. In order to document the improvement in patient care, morbidity and mortality through the implementation of the PNDS Still, deceased patients may be included in the cohort. The objective is to recruit a minimum of 200 adult patients and 300 pediatric patients so that the study has sufficient statistical power. The stratification of patients is made into 4 subgroups according to the form of the pathology: * Pediatric (juvenile arthritis systemic idiopathic) * Adult monocyclic (approximately 30% of cases) * Adult intermittent or polycyclic (30%) * Adult persistent or chronic (40%)

You may qualify if:

• Aged over 16 (age\> 16) meeting the diagnostic criteria of Yamaguchi or Fautrel criteria (appendix 5)
• Aged 16 years or less (age ≤16 years) fulfilling the 2001 criteria for ILAR systemic form of juvenile idiopathic arthritis
• Having signed a consent to participate in the cohort and in the collection of clinical and biological data; in accordance with the regulations, for patients who are minors or adults who are protected, the non-opposition of the legal representatives will be sought.
• Affiliated to the "Régime National d'Assurance Maladie".

You may not qualify if:

• Other cause of relapsing infectious fever (such as tuberculosis, toxoplasmosis, deep abscesses, viroses, sepsis) or tumor (such as lymphomas)
• Other defined inflammatory rheumatism such as rheumatoid arthritis, psoriatic arthritis, spondyloarthropathies.
• Autoimmune inflammatory disease (systemic lupus erythematosus), granulomatosis (sarcoidosis, Blau syndrome), vasculitis (Behçet's disease, nodular arteritis), polymyositis and dermatomyositis.
• Well-defined auto-inflammatory syndromes with unambiguous mutations, such as familial Mediterranean fever, cryopyrinopathies, TRAPS, mevalonate kinase deficiency.
• Known macrophage activation syndromes of genetic origin.
• Patients unable to understand the information leaflet and sign the informed consent form
• Patients not affiliated to the "Régime National d'Assurance Maladie"

Sponsors & Collaborators

• Institut National de la Santé Et de la Recherche Médicale, France: lead

Study Sites (1)

RaDiCo-AcoStill

Paris, Île-de-France Region, 75012, France

RECRUITING

MeSH Terms

Conditions

Arthritis, Juvenile; Still's Disease, Adult-Onset; Rare Diseases

Condition Hierarchy (Ancestors)

Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases; Arthritis, Rheumatoid; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Sophie Georgin-Lavialle, PHD

  INSERM U933

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Sophie Georgin-Lavialle, PHD

CONTACT

0033 156017447; sophie.georgin-lavialle@aphp.fr

Bruno Fautrel, PHD

CONTACT

bruno.fautrel@aphp.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 20, 2021
• First Posted: July 3, 2023
• Study Start: July 11, 2017
• Primary Completion (Estimated): July 1, 2027
• Study Completion (Estimated): July 1, 2027
• Last Updated: February 12, 2026

Record last verified: 2026-02

Locations

FR (1)